Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral ...

Weight loss drugs are huge these days, and Eli Lilly (LLY) is leading the pack when it comes to these. However, today’s ...

Eli Lilly forecast annual profit largely above Wall Street estimates on Thursday, banking on the launch of its popular ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

Eli Lilly reported fourth quarter and full year earnings for 2024 Thursday, with results largely beating Wall Street ...

The world’s biggest drugmaker Eli Lilly has forecast that profits for the year will beat expectations, after two choppy quarters when disappointing sales of its blockbuster weight-loss drugs led to ...

In a fresh appearance on CNBC’s Squawk on the Street, Jim Cramer cautioned viewers to not be caught up by the energy that’s ...

Danish pharmaceutical behemoth Novo Nordisk on Wednesday reported better-than-expected net profit in the fourth quarter, amid ...